Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
- Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
- Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-01-08
- Lead Sponsor
- Nabi Biopharmaceuticals
- Target Recruit Count
- 203
- Registration Number
- NCT00211939
- Locations
- 🇺🇸
University of Texas Health Sciences Center, San Antonio, Texas, United States
Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00018135
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath